Our research group examines transcriptomics, gene polymorphisms, metabolomics, and proteomics to identify biomarkers that predict disease progression and the response to antiviral therapy of individual patients chronically infected with HBV, HCV, HEV and HIV.
Transcriptomes of peripheral blood, liver cells and purified immune cells (B cell, T cell, NK cell, monocytes) obtained from patients infected with HBV, HCV, or HIV are profiled by microarray, bulk RNA-seq and single cell RNA-Seq. The transcriptomes are evaluated in detail using analyses for individual genes and gene sets/modules to understand molecular factors underlying the disease progression, differential responses to therapeutic intervention, and predictive values of gene expression.
SNP analysis and GWAS to discover genetic variants and genomic biomarkers associated with susceptibility of consecutive disease progression and to therapeutic response.
Recent Publications
- Montanari NR, et al. Multi-parametric analysis of human livers reveals intrahepatic inflammation variation across chronic hepatitis B infection phase. J Hep. 2022. 77(2): 332-343.
- Hoogeveen RC, et al. Hepatitis B virus-specific CD4 T cell responses differentiate functional cure from chronic surface antigen+ infection. J Hep. 2022. 77(5): 1276-1286.
- Gehring A, et al. Immunological Biomarker Discovery in Cure Regimens for Chronic Hepatitis B Virus Infection. J Hep. 2022. 77(2): 525-538.
- Montanari NR, et al. Transcriptomic analysis of livers of inactive carriers of hepatitis B virus with distinct expression of hepatitis B surface antigen. J Inf Dis. 2022. 225 (6): 1081-1090.
- Sonneveld MJ, et al. Hepatitis B Virus DNA and Hepatitis B e Antigen Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and Hepatitis B Antigen Loss in Hepatitis B e Antigen-Negative Patients Who Discontinued Antiviral Therapy 2023. Gastroenterol. Sep 26:S0016-5085(23)05068-0.